# Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

> **NCT03649152** · PHASE2 · COMPLETED · sponsor: **Dimerix Bioscience Pty Ltd** · enrollment: 8 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** Propagermanium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03649152
- **Lead sponsor:** Dimerix Bioscience Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-08
- **Primary completion:** 2020-06-16
- **Final completion:** 2020-07-13
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649152, "Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03649152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*